| |
| Names | |
|---|---|
| IUPAC name
(E)-N-[(4R,4aS,7aR,12bR)-3-(Cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-methylphenyl)prop-2-enamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
PubChem CID |
|
| |
| |
| Properties | |
| C30H32N2O4 | |
| Molar mass | 484.596 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Methocinnamox is an opioid antagonist.
Methocinnamox is an opioid antagonist, it works at the μ-opioid receptor.[1] By being an antagonist, it binds to the receptor but does not activate it, thus blocking the action of agonists such as Fentanyl.
In rats, methocinnamox is able to reverse the respiratory depressant effects of fentanyl. However, unlike naloxone, another opioid antagonist, its action lasts around 2 weeks if administered subcutaneously and up to 5 days if administered intravenously.[2] This could make it a better antidote than naloxoneinopioid overdoses, because naloxone usually lasts around 30 minutes, there is a need for repeated administration and a danger of renarcotization.[3] By acting longer, methocinnamox prevents these dangers.
Other tests have also shown this result, methocinnamox was able to reverse the respiratory depressant effect of heroin.
